Impact of serum apolipoproteins on the prognosis of acute ischemic stroke after thrombolysis

J Stroke Cerebrovasc Dis. 2024 Nov;33(11):107944. doi: 10.1016/j.jstrokecerebrovasdis.2024.107944. Epub 2024 Aug 15.

Abstract

Objective: The purpose of this study is to the relationship between peripheral apolipoproteins and the prognosis of patients with acute ischemic stroke (AIS) after thrombolysis.

Methods: A total of 231 AIS patients with thrombolysis was enrolled. Serum apolipoproteins were measured on admission after thrombolysis. All patients enrolled were followed up for 90 days. Their functional outcomes were assessed by the modified Rankin Scale (mRS). Good functional outcome was considered as mRS < 3. Logistic regression was applied to assess the association between serum apolipoproteins and the mRS at 90 days.

Results: In multivariate analysis,1) ApoB (OR=0.099, 95%CI=0.017∼0.575, p=0.010) and ApoB/ApoA-1(OR=0.113, 95%CI=0.015∼0.868, p=0.036) were independent risk factors of good functional outcome at 90 days. 2). there were significant differences in the mRS score distribution at 90 days in groups according to the ROC cutoff values of ApoB (0.85g/L) and ApoB/ApoA-1 ratio (0.61) (all p<0.05).

Conclusion: Our findings demonstrated ApoB and ApoB/apoA-1 ratio were independent risk factors for good functional outcome at 90 days, and the ApoB level below 0.85g/L and ApoB/ApoA-1 ratio below 0.61 could be associated with a better functional outcome in this study population.

Keywords: Acute ischemic stroke; Prognosis; Serum apolipoproteins; Thrombolysis.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Apolipoprotein A-I* / blood
  • Apolipoprotein B-100 / blood
  • Biomarkers* / blood
  • Disability Evaluation*
  • Female
  • Fibrinolytic Agents* / administration & dosage
  • Fibrinolytic Agents* / adverse effects
  • Functional Status*
  • Humans
  • Ischemic Stroke* / blood
  • Ischemic Stroke* / diagnosis
  • Ischemic Stroke* / drug therapy
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Recovery of Function*
  • Risk Assessment
  • Risk Factors
  • Thrombolytic Therapy* / adverse effects
  • Time Factors
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / adverse effects
  • Tissue Plasminogen Activator / blood
  • Treatment Outcome

Substances

  • Biomarkers
  • Apolipoprotein A-I
  • APOA1 protein, human
  • APOB protein, human
  • Fibrinolytic Agents
  • Apolipoprotein B-100
  • Tissue Plasminogen Activator